Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Baking Soda
2. Bicarbonate, Sodium
3. Carbonic Acid Monosodium Salt
4. Hydrogen Carbonate, Sodium
5. Soda, Baking
6. Sodium Hydrogen Carbonate
1. Sodium Hydrogen Carbonate
2. 144-55-8
3. Baking Soda
4. Sodium Hydrogencarbonate
5. Sodium Acid Carbonate
6. Carbonic Acid Monosodium Salt
7. Bicarbonate Of Soda
8. Sodium Hydrocarbonate
9. Monosodium Carbonate
10. Meylon
11. Acidosan
12. Neut
13. Natriumhydrogenkarbonat
14. Nahco3
15. Natrum Bicarbonicum
16. Jusonin
17. Soludal
18. Soda Mint
19. Soda (van)
20. Carbonic Acid Sodium Salt (1:1)
21. Monosodium Hydrogen Carbonate
22. Nabic
23. Mfcd00003528
24. Sodium Hydrogencarbonat
25. Hydrocerol Esc 5671
26. Carbonic Acid, Monosodium Salt
27. Genitron Tp-bch 51051
28. Sodium Bicarbonate Anhydrous
29. 8mdf5v39qo
30. E500
31. Ins No.500(ii)
32. Chebi:32139
33. Ins-500(ii)
34. Col-evac
35. Sel De Vichy
36. E-500(ii)
37. Nsc-134031
38. Natrium Bicarbonicum
39. Natrii Hydrogencarbonas
40. E 500
41. E-500
42. Natrium Hydrogencarbonicum
43. Sodium Hydrogen-carbonate
44. Caswell No. 747
45. Sodium Carbonate (na(hco3))
46. Sodium Bicarbonate (1:1)
47. Sodium Bicarbonate In Plastic Container
48. Meylon (tn)
49. Ccris 3064
50. Hsdb 697
51. Neut (tn)
52. Sodium;hydrogen Carbonate
53. Einecs 205-633-8
54. Sodium Bicarbonate Solution
55. Unii-8mdf5v39qo
56. Epa Pesticide Chemical Code 073505
57. Nsc 134031
58. Sodium Bicarbonate [usp:jan]
59. Sodium Bicabonate
60. Sodium Bicarbonat
61. Bicarbonate Sodium
62. Sodium-bicarbonate
63. Sodiumbi-carbonate
64. Sodium Bi-carbonate
65. Sodium Bicarbonate-
66. Sodium Bi Carbonate
67. Natriumhydrogencarbonat
68. Sodium Hydrogencabonate
69. Sodium;hydron;carbonate
70. Sodiumhydrogen Carbonate
71. Natrii Hydrogenocarbonas
72. Sodium Hydrogen Cabonate
73. Hydrogen Carbonate Sodium
74. Sodium Bicarbonate, Usp
75. Sodium Hyd-rogencarbonate
76. Sodium-hydrogen-carbonate
77. Sodium Hydrogen Carboante
78. Sodium Bicarboniate
79. Ec 205-633-8
80. Chembl1353
81. B1654 [langual]
82. Sodium Bicarbonate [ii]
83. Sodium Bicarbonate [mi]
84. Dtxsid9021269
85. Sodium Bicarbonate [fcc]
86. Sodium Bicarbonate [jan]
87. Sodium Bicarbonate (jp17/usp)
88. Sodium Bicarbonate [hsdb]
89. Sodium Bicarbonate [inci]
90. Sodium Hydrogen Carbonate Solution
91. Natrum Bicarbonicum [hpus]
92. Sodium Bicarbonate [vandf]
93. Sodium Bicarbonate [mart.]
94. Amy40219
95. Sodium Bicarbonate [usp-rs]
96. Sodium Bicarbonate [who-dd]
97. Str00078
98. Sodium Bicarbonate -40-+140 Mesh
99. Sodium Bicarbonate, Biochemical Grade
100. Akos015836321
101. Akos015951222
102. Sodium Hydrogen Carbonate, Puratronic?
103. Db01390
104. Sodium Bicarbonate [orange Book]
105. Baros Component Sodium Bicarbonate
106. Sodium Bicarbonate A.c.s. Reagent Grade
107. Sodium Bicarbonate [usp Monograph]
108. Bicarbonate, 1m Buffer Solution, Ph 8.0
109. Bicarbonate, 1m Buffer Solution, Ph 8.5
110. Sodium Hydrogen Carbonate [who-ip]
111. Zegerid Component Sodium Bicarbonate
112. B7292
113. Ft-0645108
114. Normocarb Component Sodium Bicarbonate
115. S0561
116. Sodium Bicarbonate Component Of Baros
117. Halflytely Component Sodium Bicarbonate
118. Sodium Bicarbonate Component Of Zegerid
119. D01203
120. Natrii Hydrogenocarbonas [who-ip Latin]
121. 3-phenyl-2-thioxotetrahydropyrimidin-4(1h)-one
122. Sodium Bicarbonate Component Of Halflytely
123. Sodium Bicarbonate Component Of Normocarb
124. Sodium Bicarbonate, 1m Buffer Solution, Ph 8.0
125. Sodium Bicarbonate, 1m Buffer Solution, Ph 9.0
126. Sodium Hydrogen Carbonate [ep Monograph]
127. Q179731
128. Sodium Bicarbonate, 1m Buffer Solution, Ph 10.0
129. Sodium Bicarbonate, Hplc, Meets Acs Specifications
130. Sodium Bicarbonate 5% W/v Solution In Water (+/- 0.3%)
131. Saturated Aqueous Sodium Bicarbonate Solution (~9.6% Wt/wt)
Molecular Weight | 84.007 g/mol |
---|---|
Molecular Formula | CHNaO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 0 |
Exact Mass | 83.98233817 g/mol |
Monoisotopic Mass | 83.98233817 g/mol |
Topological Polar Surface Area | 60.4 Ų |
Heavy Atom Count | 5 |
Formal Charge | 0 |
Complexity | 33.9 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Bss plus |
Active Ingredient | sodium chloride; sodium phosphate; magnesium chloride; potassium chloride; glutathione disulfide; sodium bicarbonate; dextrose; Calcium chloride |
Dosage Form | Solution |
Route | Irrigation |
Strength | 0.2mg/ml; 0.38mg/ml; 0.184mg/ml; 0.92mg/ml; 2.1mg/ml; 0.154mg/ml; 0.42mg/ml; 7.14mg/ml |
Market Status | Prescription |
Company | Alcon |
2 of 8 | |
---|---|
Drug Name | Golytely |
PubMed Health | Sodium Bicarbonate |
Drug Classes | Antacid, Sodium Bicarbonate Containing |
Active Ingredient | sodium chloride; sodium bicarbonate; Polyethylene glycol 3350; sodium sulfate anhydrous; potassium chloride |
Dosage Form | For solution |
Route | Oral |
Strength | 5.86gm/bot; 227.1gm/packet; 6.74gm/bot; 2.82gm/packet; 22.74gm/bot; 21.5gm/packet; 2.97gm/bot; 5.53gm/packet; 6.36gm/packet; 236gm/bot |
Market Status | Prescription |
Company | Braintree |
3 of 8 | |
---|---|
Drug Name | Nulytely |
Active Ingredient | sodium chloride; sodium bicarbonate; Polyethylene glycol 3350; potassium chloride |
Dosage Form | For solution |
Route | Oral |
Strength | 420gm/bot; 1.48gm/bot; 11.2gm/bot; 5.72gm/bot |
Market Status | Prescription |
Company | Braintree |
4 of 8 | |
---|---|
Drug Name | Sodium bicarbonate |
PubMed Health | Polyethylene Glycol 3350, Sodium and Potassium Salts (Oral route) |
Drug Classes | Laxative, Hyperosmotic |
Drug Label | Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic, hypertonic solution of sodium bicarbonate (NaHCO3) in water for injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer.Solutions are off... |
Active Ingredient | Sodium bicarbonate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.9meq/ml; 1meq/ml |
Market Status | Prescription |
Company | Hospira |
5 of 8 | |
---|---|
Drug Name | Bss plus |
Active Ingredient | sodium chloride; sodium phosphate; magnesium chloride; potassium chloride; glutathione disulfide; sodium bicarbonate; dextrose; Calcium chloride |
Dosage Form | Solution |
Route | Irrigation |
Strength | 0.2mg/ml; 0.38mg/ml; 0.184mg/ml; 0.92mg/ml; 2.1mg/ml; 0.154mg/ml; 0.42mg/ml; 7.14mg/ml |
Market Status | Prescription |
Company | Alcon |
6 of 8 | |
---|---|
Drug Name | Golytely |
PubMed Health | Sodium Bicarbonate |
Drug Classes | Antacid, Sodium Bicarbonate Containing |
Active Ingredient | sodium chloride; sodium bicarbonate; Polyethylene glycol 3350; sodium sulfate anhydrous; potassium chloride |
Dosage Form | For solution |
Route | Oral |
Strength | 5.86gm/bot; 227.1gm/packet; 6.74gm/bot; 2.82gm/packet; 22.74gm/bot; 21.5gm/packet; 2.97gm/bot; 5.53gm/packet; 6.36gm/packet; 236gm/bot |
Market Status | Prescription |
Company | Braintree |
7 of 8 | |
---|---|
Drug Name | Nulytely |
Active Ingredient | sodium chloride; sodium bicarbonate; Polyethylene glycol 3350; potassium chloride |
Dosage Form | For solution |
Route | Oral |
Strength | 420gm/bot; 1.48gm/bot; 11.2gm/bot; 5.72gm/bot |
Market Status | Prescription |
Company | Braintree |
8 of 8 | |
---|---|
Drug Name | Sodium bicarbonate |
PubMed Health | Polyethylene Glycol 3350, Sodium and Potassium Salts (Oral route) |
Drug Classes | Laxative, Hyperosmotic |
Drug Label | Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic, hypertonic solution of sodium bicarbonate (NaHCO3) in water for injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer.Solutions are off... |
Active Ingredient | Sodium bicarbonate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.9meq/ml; 1meq/ml |
Market Status | Prescription |
Company | Hospira |
Sodium bicarbonate is used in the treatment of metabolic acidosis associated with many conditions including severe renal disease (e.g., renal tubular acidosis), uncontrolled diabetes (ketoacidosis), extracorporeal circulation of the blood, cardiac arrest, circulatory insufficiency caused by shock or severe dehydration, ureterosigmoidostomy, lactic acidosis, alcoholic ketoacidosis, use of carbonic anhydrase inhibitors, and ammonium chloride administration. In metabolic acidosis, the principal disturbance is a loss of proton acceptors (e.g., loss of bicarbonate during severe diarrhea) or accumulation of an acid load (e.g., ketoacidosis, lactic acidosis, renal tubular acidosis).
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 2852
The specific role of sodium bicarbonate therapy in the treatment of diabetic ketoacidosis has not been established. Because correction of the underlying metabolic disorder generally results in correction of acid-base abnormalities and because of the potential risks of sodium bicarbonate therapy in the treatment of this disorder, administration of sodium bicarbonate is generally reserved for the treatment of severe acidosis (e.g., arterial pH less than 7-7.15 or serum bicarbonate concentration of 8 mEq/L or less). Rapid correction of acidosis with sodium bicarbonate in patients with diabetic ketoacidosis may cause hypokalemia, paradoxical acidosis in cerebrospinal fluid (CSF) since carbon dioxide diffuses more rapidly into CSF than does bicarbonate, and lactic acidosis since increased pH increases hemoglobin-oxygen affinity which, when combined with erythrocyte 2,3-diphosphoglycerate (2,3-DPG) deficiency in these patients, results in peripheral tissue hypoxia. However, the benefits and risks of sodium bicarbonate therapy in ketoacidosis have not been fully determined, and additional controlled studies of the safety and efficacy of the drug are necessary. Generally, when sodium bicarbonate is used in the treatment of diabetic ketoacidosis, the acidosis should only be partially corrected (e.g., to an arterial pH of about 7.2) to avoid rebound metabolic alkalosis as ketones are metabolized.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 2852
Oral sodium bicarbonate is indicated to reduce uric acid crystallization as an adjuvant to uricosuric medication in gout. /Included in US product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006.
Parenteral sodium bicarbonate is indicated in the treatment of certain drug intoxications, including barbiturates, and in poisoning by salicylates or methyl alcohol. /Included in US product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006.
For more Therapeutic Uses (Complete) data for Sodium bicarbonate (29 total), please visit the HSDB record page.
Sodium bicarbonate is generally contraindicated in patients with metabolic or respiratory alkalosis, in patients with hypocalcemia in whom alkalosis may induce tetany, in patients with excessive chloride loss from vomiting or continuous GI suctioning, and in patients at risk of developing diuretic-induced hypochloremic alkalosis. Sodium bicarbonate should not be used orally as an antidote in the treatment of acute ingestion of strong mineral acids, since carbon dioxide gas forms during neutralization and may cause gastric distention and possible rupture.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 2853
Sodium bicarbonate should be used with extreme caution in patients with congestive heart failure or other edematous or sodium-retaining conditions; in patients with renal insufficiency, especially those with severe insufficiency such as oliguria or anuria; and in patients receiving corticosteroids or corticotropin, since each gram of sodium bicarbonate contains about 12 mEq of sodium. IV administration of sodium bicarbonate may cause fluid and/or solute overload resulting in dilution of serum electrolytes, overhydration, congestive conditions, or pulmonary edema. The risk of dilutional conditions is inversely proportional to the electrolyte concentration administered, and the risk of solute overload and resultant congestive conditions with peripheral and/or pulmonary edema is directly proportional to the electrolyte concentration administered.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 2853
Gastric distention and flatulence may occur when sodium bicarbonate is administered orally. Inadvertent extravasation of hypertonic solutions of sodium bicarbonate has reportedly caused chemical cellulitis because of their alkalinity, subsequently resulting in tissue necrosis, ulceration, and/or sloughing at the site of injection.
American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 2853
Predisposing factors /contributing to milk-alkali syndrome/ are preexisting hypertension, sarcoidosis, dehydration and electrolyte imbalance due to vomiting or aspiration of gastric contents with inadequate iv fluid replacement, and renal dysfunction caused by primary renal disease.
American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 909
For more Drug Warnings (Complete) data for Sodium bicarbonate (14 total), please visit the HSDB record page.
Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.
Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.
B - Blood and blood forming organs
B05 - Blood substitutes and perfusion solutions
B05C - Irrigating solutions
B05CB - Salt solutions
B05CB04 - Sodium bicarbonate
B - Blood and blood forming organs
B05 - Blood substitutes and perfusion solutions
B05X - I.v. solution additives
B05XA - Electrolyte solutions
B05XA02 - Sodium bicarbonate
Elimination: Renal; carbon dioxide formed is eliminated via lungs.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006.
Excess sodium bicarbonate is emptied rapidly into small intestine where it is absorbed.
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 1043
It is eliminated principally in the urine and effectively alkalizes it. ... /It/ is completely absorbed orally and usually is excreted within 3-4 hr.
American Medical Association, AMA Department of Drugs. AMA Drug Evaluations. 4th ed. Chicago: American Medical Association, 1980., p. 1440
Oral: Onset of action: Rapid; Duration: 8-10 minutes. I.V: Onset of action: 15 minutes; duration: 1-2 hours.
Lelkin, J.B., Paloucek, F.P., Poisoning & Toxicology Compendium. LEXI-COMP Inc. & American Pharmaceutical Association, Hudson, OH 1998., p. 1079
For more Absorption, Distribution and Excretion (Complete) data for Sodium bicarbonate (8 total), please visit the HSDB record page.
Excessive use can cause systemic alkalosis /in animals/, but body usually splits bicarbonate radical into water and carbon dioxide ...
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 533
Sodium bicarbonate rapidly reacts with hydrochloric acid to form sodium chloride, carbon dioxide, and water; excess bicarbonate that does not neutralize gastric acid rapidly empties into the small intestine and is absorbed.
McEvoy, G.K. (ed.). American Hospital Formulary Service--Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, Inc. 1994 (Plus Supplements)., p. 1870
Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32237
Submission : 2017-12-13
Status : Active
Type : IV
Certificate Number : CEP 2022-467 - Rev 01
Issue Date : 2023-10-27
Type : Chemical
Substance Number : 195
Status : Valid
Date of Issue : 2020-05-20
Valid Till : 2023-02-01
Written Confirmation Number : WC-0392
Address of the Firm :
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2020-01-13
Registration Number : 20200113-211-J-530
Manufacturer Name : Emnar Pharma Private Limited
Manufacturer Address : Unit-II Plot No. 15 Jawaharlal Nehru Pharma City, Tadi (Village), Parawada (Mandal), Anakapalli (District), India.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-06-24
Pay. Date : 2021-05-17
DMF Number : 32436
Submission : 2018-01-19
Status : Active
Type : II
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2020-01-13
Registration Number : 20200113-211-J-530
Manufacturer Name : Emnar Pharma Private Limited
Manufacturer Address : Unit-II Plot No. 15 Jawaharlal Nehru Pharma City, Tadi (Village), Parawada (Mandal), Anakapalli (District), India.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38670
Submission : 2023-09-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16457
Submission : 2003-02-28
Status : Inactive
Type : II
Registration Number : 230MF40003
Registrant's Address : 13804 West 107th Street Lenexa, Kansas 66215 USA
Initial Date of Registration : 2018-01-15
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19557
Submission : 2006-05-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19772
Submission : 2006-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21368
Submission : 2008-02-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21545
Submission : 2008-03-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12585
Submission : 1997-07-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21689
Submission : 2008-07-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15236
Submission : 2000-12-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20090
Submission : 2006-12-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19557
Submission : 2006-05-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21545
Submission : 2008-03-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16457
Submission : 2003-02-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21368
Submission : 2008-02-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19772
Submission : 2006-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25850
Submission : 2012-03-05
Status : Inactive
Type : II
Certificate Number : CEP 2022-467 - Rev 01
Status : Valid
Issue Date : 2023-10-27
Type : Chemical
Substance Number : 195
Certificate Number : CEP 2022-300 - Rev 00
Status : Valid
Issue Date : 2024-02-22
Type : Chemical
Substance Number : 195
Certificate Number : R1-CEP 2006-043 - Rev 00
Status : Valid
Issue Date : 2012-03-13
Type : Chemical
Substance Number : 195
Certificate Number : R0-CEP 2020-228 - Rev 00
Status : Valid
Issue Date : 2022-04-08
Type : Chemical
Substance Number : 195
Certificate Number : R1-CEP 2004-252 - Rev 01
Status : Valid
Issue Date : 2017-01-24
Type : Chemical
Substance Number : 195
About the Company : Pharm-Rx has earned an outstanding reputation since its establishment in 1991, serving as a reputable importer and distributor of active ingredients to the pharmaceutical, nutritio...
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
About the Company : Brenntag is the global market leader in providing a full range of chemicals and ingredients and value-added services. By connecting chemical manufacturers (our suppliers) and chemi...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Macco Organiques, s.r.o. in the Czech Republic is a prominent producer and supplier of inorganic salts utilized in various industries, including IV and dialysis solutions, pharmace...
About the Company : Nitika Pharmaceutical Specialities was found in 1991 as a small manufacturing unit has grown today into a dynamic production center for a range of products finding applications in ...
About the Company : Spectropharma, a Saudi Arabian company founded in 2019, focuses on the development, manufacturing, and sales of pharmaceutical products within Saudi Arabia and internationally.Cons...
About the Company : Sudeep Pharma Pvt. Ltd. is a leading producer of Calcium based Pharmaceutical, Food and Feed ingredients in India for the last quarter of a century. Established in 1989, we are one...
About the Company : Valaji PharmaChem is an ISO certified and a leading name in the field of Fine/ Specialty high purity chemicals with large manufacturing facilities located at Padra, Baroda, Gujarat...
About the Company : Vasa Pharmachem Pvt. Ltd. established in the year 1988, is a part of the diversified Vasa Group of companies.Company was established to support a wide range of industries by manufa...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
ARINA-1 is a new nebulized product composed of ascorbic acid, glutathione, and bicarbonate, currently in phase 2 trials for treating patients with Non-cystic Fibrosis Bronchiectasis.
Lead Product(s): Ascorbic Acid,Glutathione,Sodium Bicarbonate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Arina-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Lead Product(s) : Ascorbic Acid,Glutathione,Sodium Bicarbonate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renovion Reports Positive Results from Phase 2 CLIMB Study of ARINA-1
Details : ARINA-1 is a new nebulized product composed of ascorbic acid, glutathione, and bicarbonate, currently in phase 2 trials for treating patients with Non-cystic Fibrosis Bronchiectasis.
Brand Name : Arina-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Details:
The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.
Lead Product(s): Sodium Chloride,Sodium Bicarbonate,Potassium Chloride
Therapeutic Area: Gastroenterology Brand Name: Movicol
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs Asset Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 15, 2022
Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs Asset Management
Deal Size : Undisclosed
Deal Type : Financing
Norgine Announces Closing of Investment from Goldman Sachs Asset Management
Details : The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.
Brand Name : Movicol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 15, 2022
Details:
KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Brand Name: Konvomep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Azurity Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Azurity Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients...
Brand Name : Konvomep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2022
Details:
Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Brand Name: Konvomep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep™ (Omeprazole and Sodium Bicarbo...
Details : Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Brand Name : Konvomep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 02, 2022
Details:
Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Brand Name: Zegerid
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Carlin Consumer Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 01, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Carlin Consumer Health
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.
Brand Name : Zegerid
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 01, 2022
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG;1.1GM
Approval Date : 2016-07-15
Application Number : 204068
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 40MG;1.1GM
Approval Date : 2016-07-15
Application Number : 204068
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code :
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 20MG/PACKET;1.68GM/PACKET
Approval Date : 2024-05-09
Application Number : 217784
RX/OTC/DISCN : OTC
RLD : No
TE Code :
RLD : No
TE Code :
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG;1.1GM
Approval Date : 2010-05-25
Application Number : 78966
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 40MG;1.1GM
Approval Date : 2010-05-25
Application Number : 78966
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 20MG/PACKET;1.68GM/PACKET
Approval Date : 2013-04-19
Application Number : 79182
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 40MG/PACKET;1.68GM/PACKET
Approval Date : 2013-04-19
Application Number : 79182
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
OMEPRAZOLE; SODIUM BICARBONATE
Brand Name : OMEPRAZOLE AND SODIUM BICARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG;1.1GM
Approval Date : 2016-07-15
Application Number : 201946
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AA
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS
Brand Name : POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES
Dosage Form : FOR SOLUTION;ORAL
Dosage Strength : 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT
Approval Date : 2018-12-21
Application Number : 204558
RX/OTC/DISCN : RX
RLD : No
TE Code : AA
RLD : No
TE Code : AA
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
Brand Name : PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE
Dosage Form : FOR SOLUTION;ORAL
Dosage Strength : 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT
Approval Date : 2015-04-13
Application Number : 204559
RX/OTC/DISCN : RX
RLD : No
TE Code : AA
Regulatory Info :
Registration Country : Norway
Macrogol 3350, sodium chloride, sodium hydrogen carbonate, potassium chloride
Brand Name : Macrovic
Dosage Form : Powder for oral solution, solution in sachet
Dosage Strength :
Packaging : Dosepose 100item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Sodium Bicarbonate
Brand Name : Re-Hydration Electrolytic Ii
Dosage Form :
Dosage Strength : 1 Bottle 1,000 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Sodium Bicarbonate
Brand Name : Re-Hydration Electrolytic Ii
Dosage Form :
Dosage Strength : 1 Bag 500 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Turkey
sodium alginate; Sodium Bicarbonate; Calcium Carbonate
Brand Name : Refubel
Dosage Form : Oral Suspension
Dosage Strength : 0.5G/10ML; 0.267G/10ML; 0.160G/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Regulatory Info :
Registration Country : Norway
Macrogol 3350, sodium chloride, sodium hydrogen carbonate, potassium chloride
Brand Name : Movicol
Dosage Form : Powder for oral solution, solution in sachet
Dosage Strength :
Packaging : Dosepose 100 1item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : Sodium Bicarbonate
Dosage Form :
Dosage Strength : 1 Bottle 500 Ml 1,4%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Sodium Bicarbonate
Dosage Form :
Dosage Strength : 1 Bag 500 Ml 1,4%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Sodium Bicarbonate
Dosage Form :
Dosage Strength : 1 Bottle 250 Ml 1,4%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Sodium Bicarbonate
Dosage Form :
Dosage Strength : 1 Bottle 500 Ml 8.4%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Bicarbonate; Potassium Bicarbonate
Brand Name : Sodium Bicarbonate, Potassium Bicarbonate
Dosage Form :
Dosage Strength : 5 Vials 20 Meq 20 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : PHYSIONEAL 40 GLUCOSE 2.27%
Dosage Form : SOLUTION
Dosage Strength : 3.29G/L
Packaging :
Approval Date :
Application Number : 2247722
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : PHYSIONEAL 40 GLUCOSE 3.86%
Dosage Form : SOLUTION
Dosage Strength : 3.29G/L
Packaging : 2L/2.5L
Approval Date :
Application Number : 2247723
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : PHYSIONEAL 40 GLUCOSE 2.27% CLEAR-FLEX
Dosage Form : SOLUTION
Dosage Strength : 9.29G/L
Packaging :
Approval Date :
Application Number : 2368757
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : BICART
Dosage Form : POWDER
Dosage Strength : 720G/CARTRIDGE
Packaging :
Approval Date :
Application Number : 2403498
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : BICART SELECT COMBI-PAK
Dosage Form : KIT
Dosage Strength : 720G/CARTRIDGE
Packaging :
Approval Date :
Application Number : 2425246
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : BIBAG
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 650G/BAG
Packaging : 650G
Approval Date :
Application Number : 2325586
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : PEGLYTE POWDER
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 6.76G/BOTTLE
Packaging : 280G - 4X70G
Approval Date :
Application Number : 777838
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : COLYTE
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 24.02MG/G
Packaging : 278G PER 4L
Approval Date :
Application Number : 677442
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : BI-PEGLYTE
Dosage Form : TABLET (DELAYED-RELEASE)
Dosage Strength : 1.69G/SACHET
Packaging : 3 TABS- 2 SACHETS
Approval Date :
Application Number : 2326302
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : SODIUM BICARBONATE INJECTION USP
Dosage Form : SOLUTION
Dosage Strength : 84MG/ML
Packaging : 10ML/50ML
Approval Date :
Application Number : 261998
Regulatory Info : Ethical
Registration Country : Canada
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Application : Co-Processed Excipients
Excipient Details : Mannitol is a co-processed excipient with superior compactibility, lower disintegration time, and hygroscopicity.
Dosage Form : Cream / Lotion / Ointment, Emulsion, Gel, Injectable / Parenteral, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Category : Parenteral, Thickeners and Stabilizers
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Dosage Form : Cream / Lotion / Ointment, Emulsion, Injectable / Parenteral, Softgels, Tablet
Grade : Oral, Topical, Parenteral
Category : Film Formers & Plasticizers, Parenteral, Topical
Dosage Form : Capsule, Cream / Lotion / Ointment, Emulsion, Gel, Injectable / Parenteral, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.
Dosage Form : Capsule, Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Solution, Tablet
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 4000
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 4000 is used as a thickener & suspending agent in suspension injections. It is also used as plasticizer, binder, lubricant & solubilizer.
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgels
Grade : Parenteral, Oral, Topical
Category : Film Formers & Plasticizers, Parenteral, Thickeners and Stabilizers, Topical
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?